Find Out if Leqembi Is the Hero Aduhelm Wasn’t
April 2023
You’ll hear buzz about a new Alzheimer’s med, Leqembi (lecanemab).
It joins Aduhelm (aducanumab) as the second IV monoclonal antibody to treat mild Alzheimer’s disease. It’s NOT for dementia without amyloid beta plaque or more severe disease.
Aduhelm and Leqembi are being touted as “disease-modifying” because they decrease amyloid plaque. But this surrogate marker isn’t shown to improve Alzheimer’s disease yet.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote